Non-chlorofluorocarbon aerosol formulations

Abstract

Aerosol formulations substantially free of chlorofluorocarbons for oral and/or nasal administration are described. The formulations comprise 1,1,1,2,3,3,3-heptafluoropropane, a medicament, optionally an excipient and optionally a surfactant. Methods of treatment utilizing the formulations are also described.

Description

INTRODUCTION TO THE INVENTION

The present invention is directed at aerosol formulations which are substantially free of chlorofluorocarbons (CFC's). More specifically, the present invention is directed at formulations substantially free of CFC's and having particular utility in medicinal applications, especially in metered dose pressurized inhalators (MDI's).

Metered dose inhalators have proven to be an effective method for delivering medicaments orally and nasally. They have been used extensively for delivering bronchodilating and steroidal compounds to asthmatics and may also be useful for delivering other compounds such as pentamidine and non-bronchodilator anti-inflammatory drugs. The rapid onset of activity of compounds administered in this manner and the absence of any significant side effects have resulted in a large number of compounds being formulated for administration via this route. Typically, the drug Is delivered to the patient by a propellant system generally comprising one or more propellents which have the appropriate vapor pressure and which era suitable for oral or nasal administration, The more preferred propellant systems typically comprise propellant 11, propellant 12, propellant 114 or mixtures thereof. Often the vapor pressure of the propellant systems is adjusted by admixing a liquid excipient with the propellant.

However, propellants 11, 12 and 114 belong to a class of compounds known as chlorofluorocarbons, which have been linked to the depletion of ozone in the atmosphere. It has been postulated that ozone blocks certain harmful UV rays and the a decrease in the atmospheric ozone content will result in an increase in the incidence of skin cancer. In the 1970's certain steps were taken to reduce the CFC emissions from aerosols. Other propellents, such as hydrocarbons, were used, or the product was delivered in a different manner. Because CFC usage in medicine; applications is relatively low i.e. less than 1% of total CFC emissions, and because of the health benefits associated with metered dose Inhalators, steps were not taken at that time to restrict the use of CFC propellents in metered dose inhalators.

However, continuing and more sophisticated ozone measurements have indicated that the earlier restrictions in CFC usage were insufficient and that additional, significant steps should be taken to drastically reduce CFC emissions. Recently, recommendations have been made that CFC production be virtually discontinued by the end of this century. As a result, it may not be possible to continue to use CFC propellents in the Intermediate and long term. While some efforts have been made to use non-pressurized metered dose inhalators, many of these devices have not been completely successful. Many do not deliver uniform doses, are mechanically complex, do not provide the 100-200 doses per unit of current aerosol containers, are difficult for individuals to utilize, and are bulky and/or cumbersome for the patients to use, particularly when they have an acute need for the medication.

As a result, there is a need for aerosol formulations which are substantially free of CFC's. Non-CFC propellents systems must meet several criteria for pressurized metered dose inhalators. They must be non-toxic, stable and non-reactive with the medicament and the other major components in the valve/actuator. One propellant which has been found to be suitable is CF.sub.3 --CH.sub.2 F--CF.sub.3, also known as Freon 227, HFA 227, HFC 227 or 1,1,1,2,3,3,3 heptafluoropropane. However, certain physical properties, i.e., polarity and solubility, of HFC 227 differ from those of commonly used CFC propellents. Commonly used surfactants may be insoluble in HFA 227. Moreover, where the medicament is to be delivered as a solution, the medicament may not be readily soluble In this propellant, The polarity difference between HFC 227 and the previously used CFC propellents may result in a different delivery of the medicament when HFC 227 replaces a CFC propellant. The medicament may cream, settle or agglomerate in the non-CFC propellant even though this did not occur in the CFC propellant.

The use of HFA 227 previously has been disclosed for use in medicinal inhalators. European Patent Publication No. 0 384 371 is directed at the combination of propellant 227 and propane, butane, isobutane, Me.sub.2 O and/or F.sub.2 CHMe.

Research Disclosure No. 30161, May, 1989 discloses that non-CFC propellents, such as fluorohydrocarbons may be used in pressurized medicaments delivered directly to the lungs, e.g. bronchodilators.

Other publications have been directed at the use of other fluorohydrocarbons, such as HFC 134a, for aerosol propellents. European Patent Publication No. 0 372 777 is directed at medicinal aerosol formulations incorporating HFC 134a and an adjuvant having a higher polarity than the propellant. This publication lists several possible adjuvants end surfactants for use in combination with the propellant and the medicament.

International patent application No. WO 91/04011 discloses the combination of HFC 134a and a powdered medicament pre-coated with a non-perfluorinated surfactant prior to dispersing the powdered medicament in the propellant. Pages 6-7 of the publication list suitable surfactants for use with the propellant. A perfluorinated adjuvant optionally could be added. However, the pre-coating of the medicament may not be advantageous, since it adds an additional, complex step to the manufacturing process.

U.S. Pat. No. 4,174,295 discloses the combination of HFC 134a with various chlorofluorocarbons and optionally a saturated hydrocarbon. U.S. Pat. No. 2,885,427 discloses the use of HFC-134a as an aerosol propellant. U.S. Pat. No. 3,261,748 discloses the use of HFC-134a for anesthesia. U.S. Pat. Nos. 4,129,603, 4,311,863, 4,851,595 end European Publication No. 379,793 also disclose the use of HFC-134a as an aerosol propellant.

However, the specific combinations noted above may not provide the desired solubility, stability, low toxicity, exact dosage, correct particle size (if suspension) and/or compatibility with commonly used valves assemblies of mete red dose inhalers.

SUMMARY OF THE INVENTION

Accordingly, the present invention is directed at non-toxic formulation substantially free of CFC's having improved stability and compatibility with the medicament and which is relatively easily manufactured.

The present invention also is directed at formulations which may be utilized in present aerosol filling equipment with only relatively minor modifications and without pro-coating the medicament.

One embodiment of the present Invention is directed at a formulation comprising:

A. Propellant 1,1,1,2,3,3,3 heptafluoropropane; B. optionally an excipient selected from the group consisting of alcohols, Miglyol 812, Miglyol 840, PEG-400, menthol, lauroglycol, Vertrel 245, Transcutol, Labrafac Hydro WL 1219, perfluorocyclobutane, eucalyptus oil, short chain fatty adds, and combinations thereof; C. a medicament; and D. optionally a surfactant selected from the group consisting of oleic acid, sorbitan trioleate, cowl pyridinium chloride, soys lecithin, Tween 20, Tween 60, Tween 80, Pluronic L-121 and Pluronic L-92, castor oil ethoxylate, pluronic F 68, Tetronic 150 R1 and combinations thereof.

Also included within the invention is an aerosol formulation comprising:

A. an effective amount of medicament; B. 1,1,1,2,3,3,3 heptafluoropropane; and C. an excipient selected from the group consisting of: propylene glycol diesters of medium chain fatty acids; triglyceride esters of medium chain fatty acids; perfluorodimothylcyclobutane; perfluorocyclobutane; polyethylene glycol; menthol; lauroglycol; diethylene glycol monoethylether; polyglycolized glycerides of medium chain fatty acids; alcohols; eucalyptus oil; short chain fatty acids; and combinations thereof.

The formulation optionally may further comprise a surfactant. The surfactant preferably is selected from the group consisting of:

oleic acid; sorbitan trioleate; cetyl pyridinium chloride; soya lecithin; polyoxyethylene(20) sorbitan monolaurate; polyoxyethylene (10) stearyl ether; polyoxyethylene (2) oleyl other; polyoxypropylene-polyoxyethylene-ethylene diamine block copolymers; polyoxyethylene(20) sorbitan monostearate; polyoxyethylene(20) sorbitan monooleate; polyoxypropylene-polyoxyethylene block copolymers; castor oil ethoxylate; and combinations thereof.

The preferred liquid excipients are diethylene glycol monethyether, propyleneglycol diesters of medium chain fatty acids, perfluorodimethylcyclobutane and polyethylene glycol.

The preferred surfactants are oleic acid; sorbitan trioleate, cetylpyridinium chloride; polyoxyethylene (20) sorbitan monolaurate; polyoxypropylene-polyoxyethylene block copolymers; soys lecithin; and polyoxypropylene-polyoxyethylene-ethylenediamine block copolymers; with oleic acid being particularly preferred.

The invention is of particular utility where the medicament is albuterol, mometasone furoate or beclomethasone dipropionate, end salts and clathrates thereof.

A useful formulation range comprises:

______________________________________A. 1,1,1,2,3,3,3 heptafluoropropane 25-99.99 wt %B. medicament 0.01-1 wt %C. excipient 0-75 wt %D. surfactant 0-3 wt %______________________________________

The present invention also is directed at a method of treating asthma in mammals comprising administering to a mammal in need of such treatment an effective amount of aerosol formulation comprising:

A. a medicament selected from the group comprising albuterol, mometasone furoate, beclomethasone dipropionate, and salts and clathrates thereof; B. 1,1,1,2,3,3,3 heptafluoropropane; and C. optionally an excipient selected from the group consisting of: propylene glycol diesters of medium chain fatty acids; triglyceride esters of medium chain fatty acids; perfluorodimethylcyclobutane; perfluorocyclobutane; polyethylene glycol; menthol; lauroglycol; diethyleneglycol monoethylether; polyglycolized glycerides of medium chain fatty acids; alcohols; short chain fatty acids; eucalyptus oil and combinations thereof.

A surfactant optionally is present. The surfactant preferably is selected from the group consisting of:

oleic acid; sorbitan trioleate; cetyl pyridinium chloride; soya lecithin; polyoxyethylene (20) sorbitan monolaurate; polyoxyethylene (10) stearyl ether; polyoxyethylene (2) oleyl other; polyoxyethylene-polyoxypropylene-ethylene diamine block copolymers; polyoxyethylene (20) sorbitan monostearate; polyoxypropylene-polyoxyethylene block copolymers; castor oil ethoxylate; and combinations thereof.

DETAILED DESCRIPTION OF THE INVENTION

The formulations of the present invention all utilize propellant 227 in combination with the medicament, optionally a liquid excipient and optionally a surfactant.

The excipient facilitates the compatibility of the medicament with the propellant and also lowers the discharge pressure to an acceptable range i.e. about 2.76-5.52.times.10.sup.5 newton/meter.sup.2 absolute (40 to 80 psia), preferably 3.45-4.83.times.10.sup.5 newton/meter.sup.2 absolute (50 to 70 psia). The excipient chosen must be non-reactive with the medicament, relatively non-toxic, and should have a vapor pressure below about 3.45.times.10.sup.5 newton/meter.sup.2 absolute (50 psia). As used hereinafter the term "medium chain fatty acids" refers to chains of alkyl groups terminating in a --COOH group and having 6-12 carbon atoms, preferably 8-10 carbon atoms. The term "short chain fatty acids" refers to chains of alkyl groups terminating in a --COOH group and having 4-8 carbon atoms. The term "alcohol" includes C.sub.1 -C.sub.3 alcohols, such as methanol, ethanol and isopropanol. Among the preferred excipients are:

propylene glycol diesters of medium chain fatty acids available under the tradename Miglyol 840 (from H01s America, Inc. Piscataway, N.J.); triglyceride esters of medium chain fatty adds available under the tradename Miglyol 812 (from Huls); perfluorodimethylcyclobutane available under the tradename Vertrel 245 (from E. I. DuPont de Nemours and Co. Inc. Wilmington, Del.); perfluorocyclobutane available under the tradename octafluorocyclobutane (from PCR Gainsville, Fla.); polyethylene glycol available under the tradename PEG 400 (from BASF Parsippany, N.J.); menthol (from Pluess-Stauffer International Stanford, Conn.); propylene glycol monolaurate available under the tradename lauroglycol (from Gattefosse Elmsford, N.Y.); diethylene glycol monoethylether available under the tradename Transcutol (from Gattefosse); polyglycolized glyceride of medium chain fatty adds available under the tradename Labrafac Hydro WL 1219 (from Gattefosse); alcohols, such as ethanol, methanol and isopropanol; eucalyptus oil available (from Pluses-Stauffer International); end mixtures thereof.

A surfactant optionally may be added to lower the surface and Interfacial tension between the medicament and the propellant. Where the medicament, propellant and excipient are to form a suspension, a surfactant may or may not be required. Where the medicament, propellant and excipient are to form a solution, a surfactant may or may not be necessary, depending in part, on the solubility of the particular medicament and excipient. The surfactant may be any suitable, non-toxic compound which is non-reactive with the medicament and which substantially reduces the surface tension between the medicament, the excipient and the propellant and/or acts as a valve lubricant. Among the preferred surfactants are:

oleic acid available under the tradename oleic acid NF6321 (from Henkel Corp. Emery Group, Cincinnati, Ohio); cetylpyridinium chloride (from Arrow Chemical, Inc. Westwood, N.J.); soya lecithin available under the tradename Epikuron 200 (from Lucas Meyer Decatur, Ill.); polyoxyethylene(20) sorbitan monolaurate available under the tradename Tween 20 (from ICI Specialty Chemicals, Wilmington, Del.); polyoxyethylene(20) sorbitan monostearate available under the tradename Tween 60 (from ICI); polyoxyethylene(20) sorbitan monooleate available under the tradename Tween 80 (from ICI); polyoxyethylene (10) stearyl ether available under the tradename Brij 76 (from ICI); polyoxyethylene (2) oleyl ether available under the tradename Brij 92 (frown ICI); Polyoxyethylene-polyoxypropylene-ethylenediamine block copolymer available under the tradename Tetronic 150 R1 (from BASF); polyoxypropylene-polyoxyethylene block copolymers available under the tradenames Pluronic L-92, Pluronic L-121 end Pluronic F 68 (from BASF); castor oil ethoxylate available under the tradename Alkasurf CO-40 (from Rhone-Poulenc Mississauga Ontario,Canada); and mixtures thereof.

The medicaments of the present invention may include any pharmaceutically active compounds which are to be delivered by oral inhalation or nasally. Typical classes of compounds include bronchodilators, anti-inflammatory compounds, antihistamines, antiallergics, analgesics, antitussives, anti-anginal medications, steroids, corticosteroids, vasoconstrictors and antibiotics. Specific compounds within these classes of compounds are albuterol, mometasone furoate, beclomethesone dipropionate, isoproterenol, haperin, terbuteline, rimiterol, pirbuterol, disodium cromoglycate, isoprenaline, adrenaline, pentamidine and ipratropium bromide. These compounds may be utilized either as the free base, as a salt, or as a clathrate, depending upon the stability and solubility of the active compound in the specific formulation. When clathrates are utilized, P-11 and hexane clathrates are particularly preferred.

Where the active compound forms a suspension, the particle size should be relatively uniform, with substantially all the particles preferably ranging between about 0.1-25 microns, preferably 0.5-10 microns, more preferably 1-5 microns. Particles larger than 25 microns may be held up in the oropharyngeal cavity, while particles smaller than about 0.5 micron preferably are not utilized, since they would be more likely to be exhaled and, therefore, not reach the lungs of the patient.

The formulations of the present invention may be filled into the aerosol containers using conventional filling equipment. Since propellant 227 may not be compatible with all elastomeric compounds currently utilized in present aerosol valve assemblies, it may be necessary to substitute other materials, such as white buns rubber, or to utilize excipients and optionally surfactants which mitigate the adverse effects of propellant 227 on the valve components.

To assure uniform dispersion of the active Ingredient, the formulations typically will include the following components:

______________________________________ Preferred Most Preferred Range (wt %) Range (wt %) Range (wt %)______________________________________Medicament 0.01-1 0.03-0.7 0.05-0.5Propellant 25-99.99 50-99.97 50-99.95Excipient(s) 0-75 0-50 0-50Surfactant(s) 0-3 0-2 0-1______________________________________

Depending on the particular application, the container may be charged with a predetermined quantity of formulation for single or multiple dosing. Typically, the container is sized for multiple-dosing, and, therefore, it is very Important that the formulation delivered is substantially uniform for each dosing. For example, where the formulation is for bronchodilation, the container typically is charged with a sufficient quantity of the formulation for 200 charges.

Suitable suspensions may be screened in part by observing several physical properties of the formulation, i.e. the rate of particle agglomeration, the size of the agglomerates and the rate of particulate creaming/settling and comparing these to an acceptable standard. Suitable solutions may be screened by observing the solubility of the medicament over the entire recommended storage temperature range.

Suspensions of the present invention preferably may be prepared by either the pressure filling or cold filling procedures well-known in the art.

For metered dose inhalators, suspensions may be particularly preferred for efficacy and stability considerations.

Those skilled in the art may choose to add one or more preservative, buffer, antioxidant, sweetener and/or flavors or other taste masking agents depending upon the characteristics of the formulation.

Examples I-XXXIII below further describe the present invention. For several of the examples, alternative formulations denoted as A and B are provided.

______________________________________Component Wt %______________________________________ A B______________________________________EXAMPLE IAlbuterol 0.5 0.1Miglyol 812 10.0 1.0HFC-227 89.5 98.9EXAMPLE IIAlbuterol 0.1Transcutol 25.0HFC-227 74.9EXAMPLE IIIAlbuterol 0.5 0.1Miglyol 840 10.0 1.0HFC-227 89.5 98.9EXAMPLE IVAlbuterol 0.1PEG 400 1.0HFC-227 98.9EXAMPLE VAlbuterol 0.1Menthol 0.5HFC 227 98.9EXAMPLE VIAlbuterol 0.1 0.1Lauroglycol 0.1 0.5HFC 227 99.8 99.4EXAMPLE VIIAlbuterol 0.1 0.5Ventrel 245 10.0 49.6HFC 227 89.9 49.9EXAMPLE VIIIAlbuterol 0.1Labrafac Hydro WL 1219 0.5HFC 227 99.4EXAMPLE IXAlbuterol 0.1 0.5Perfluorocyclobutane 10.0 49.6HFC 227 89.9 49.9EXAMPLE XOleic Acid 0.01 0.1Albuterol 0.10 0.1Ethanol 1.00 30.0HFC 227 98.89 69.8EXAMPLE XIOleic Acid 0.01 0.1Albuterol sulfate 0.10 0.1Ethanol 1.00 30.0HFC 227 98.89 69.8EXAMPLE XIIOleic Acid 0.01 0.1Albuterol 0.10 0.1Ethanol 1.00 25.0HFC 227 98.89 74.8EXAMPLE XIIIOleic Acid 0.001 0.01Albuterol 0.1 0.1Miglyol 812 1.0 10.0HFC 227 98.8 89.8EXAMPLE XIVTetronic 150 R1 0.1Albuterol 0.1Miglyol 812 9.8HFC-227 90EXAMPLE XVPluronic L121 0.1 0.1Albuterol 0.1 0.1Miglyol 812 1.0 10.0HFC 227 98.8 89.8EXAMPLE XVITween 20 0.1Albuterol 0.1Miglyol 812 10.0Vertrel 245 10.0HFC-227 79.8EXAMPLE XVIIOleic Acid 0.01 0.1Albuterol Sulfate 0.10 0.1Ethanol 1.00 25.0HFC 227 98.89 74.8EXAMPLE XVIIIOleic Acid 0.01 0.1Albuterol Sulfate 0.10 0.1Transcutol 1.00 25.0HFC 227 98.89 74.8EXAMPLE XIXPluronic L 121 0.1 0.1Monetasone Furoate 0.1 0.1Miglyol 812 1.0 10.0HFC 227 98.8 89.8EXAMPLE XXTetronic 150 R1 0.1Mometasone Furoate 0.1Miglyol 812 9.8HFC-227 90 EXAMPLE XXIMometasone Furoate 0.1HFC-227 99.9EXAMPLE XXIIBeciomethasone Dipropionate 0.1HFC-227 99.9EXAMPLE XXIIIMometasone Furoate 0.1Tween 20 0.01HFC-227 99.89EXAMPLE XXIVBeciomethasone Dipropionate 0.1Tween 20 0.01HFC-227 99.89EXAMPLE XXVMometasone Furoate 0.1Tween 20 0.01Oleic Acid 0.0005HFC-227 99.8895EXAMPLE XXVIBeciomethasone Dipropionate 0.1Tween 20 0.01Oleic Acid 0.0005HFC-227 99.8895EXAMPLE XXVIIMometasone Furoate 0.1Miglyol 812 9Oleic Acid 0.005Tetronic 150 R1 0.01HFC-227 90.885EXAMPLE XXVIIIBeciomethasone Diproprionate 0.1Miglyol 840 9Oleic Acid 0.005Pluronic L121 0.01HFC-227 90.885EXAMPLE XXIXOleic Acid 0.001 0.01Mometasone Furoate 0.1 0.1Miglyol 812 1.0 10.0HFC 227 98.8 89.8EXAMPLE XXXPluronic L121 0.1 0.1Beciomethasone Dipropionate 0.1 0.1Miglyol 812 1.0 10.0HFC 227 98.8 89.8EXAMPLE XXXIBeciomethasone Dipropionate 0.1 0.1Miglyol 812 1.0 10.0HFC 227 98.9 89.9EXAMPLE XXXIIBeciomethasone Dipropionate 0.1 0.1PEG 400 1.0 10.0HFC 227 98.9 89.9EXAMPLE XXXIIIBeciomethasone Dipropionate 0.1Ethanol 5HFC 227 94.9______________________________________

While the examples above have been directed at albuterol, albuterol sulfate, mometasone furoate, beclomethasone dipropionate and beclomethasone dipropionate clathrates, it is contemplated that other orally Or nasally administered medicaments could be utilized. Similarly, it is contemplated that excipients and surfactants other than those exemplified may be utilized.

The descriptions of the foregoing embodiments of the invention have been presented for the purpose of illustration and description. They are not intended to be exhaustive or to limit the invention to the precise forms disclosed, and obviously many modifications and variations am possible in light of the above teaching. The embodiments were chosen and described in order to best explain the principles of the invention and its practical application to thereby enable others skilled in the art to best utilize the invention in various embodiments and with various modifications as are suited to the particular use contemplated. It is intended that the scope of the invention be defined by the claims appended hereto.

Claims

1. An aerosol formulation consisting essentially of:

A. an effective amount of a medicament;

B. 1,1,1,2,3,3,3-heptafluoropropane;

C. optionally, an excipient selected from the group consisting of a propylene glycol diester of a medium chain fatty acid and a triglyceride ester of a medium chain fatty acid, a surfactant being optionally present together with the excipient; and

D. optionally, one or more components selected from one or more of the following:

preservatives;

buffers;

antioxidants;

sweeteners; and

taste masking agents.

2. The formulation of claim 1 wherein the medicament is selected from the group consisting of: albuterol; mometasone furoate; beclomethasone dipropionate; isoproterenol; heparin; terbutaline; rimiterol; pirbuterol; disodium cromoglycate; isoprenaline, adrenaline, pentamidine; ipratropium bromide; and salts and clathrates thereof.

3. The formulation of claim 1 wherein the medicament is selected from the group consisting of: albuterol; albuterol sulfate; beclomethasone dipropionate; beclomethasone dipropionate clathrates; and mometasone furoate.

4. The formulation of claim 1 containing 0.01 to 1 percent by weight medicament.

5. The formulation of claim 1 containing 0.03 to 0.7 percent by weight medicament.

6. The formulation of claim 1 containing 0.05 to 0.5 percent by weight medicament.

7. The formulation of claim 1 wherein the medicament is a powder having a mean particle size of 1 to 5 microns.

8. An aerosol formulation consisting essentially of:

A. a medicament selected from the group consisting of albuterol, mometasone furoate, beclomethasone dipropionate, and salts and clathrates thereof;

B. 1,1,1,2,3,3,3-heptafluoropropane;

C. optionally, an excipient selected from the group consisting of a propylene glycol diester of a medium chain fatty acid and a triglyceride ester of a medium chain fatty acid, a surfactant being optionally present together with the excipient; and

D. optionally, one or more components selected from one or more of the following:

preservatives;

buffers;

antioxidants;

sweeteners; and

taste masking agents.

9. An aerosol formulation consisting essentially of:

A. an effective amount of mometasone furoate;

B. 1,1,1,2,3,3,3-heptafluoropropane; and

C. optionally, one or more components selected from at least one of the following:

excipients;

surfactants; and

additives which are:

preservatives;

buffers;

antioxidants;

sweeteners; and

taste masking agents.

10. The formulation of claim 9 containing the following:

______________________________________Component Weight Percent______________________________________Mometasone Furoate 0.01-11,1,1,2,3,3,3-Heptafluoropropane 25-99.99Excipient 0-75Surfactant 0-3.______________________________________

11. The formulation of claim 10 containing the following:

______________________________________Component Weight Percent______________________________________Mometasone Furoate 0.03-0.71,1,1,2,3,3,3-Heptafluoropropane 50-99.97Excipient 0-50Surfactant 0-2.______________________________________

12. The formulation of claim 11 containing the following:

______________________________________Component Weight Percent______________________________________Mometasone Furoate 0.05-0.51,1,1,2,3,3,3-Heptafluoropropane 50-99.95Excipient 0-50Surfactant 0-1.______________________________________

13. The formulation of claim 9 which is substantially free of chlorofluorocarbons.